← Every company
Madrigal Pharmaceuticals Inc Patents
What Madrigal Pharmaceuticals Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
MDGL on carbonthat →Filings on file
27
Granted
3
Still pending
24
Filed under
2 names
27 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| METHODS FOR TREATING A FATTY LIVER DISEASEA61P 1/16, A61K 31/53Filed as Madrigal Pharmaceuticals, Inc.2025-12-10REBECCA TAUB | 12667575 |
| RESMETIROM FOR REDUCING LIVER VOLUMEA61K 31/501, A61K 31/53, A61P 1/16Filed as Madrigal Pharmaceuticals, Inc.2025-11-12REBECCA TAUB | 12661361 |
| METHODS FOR TREATING CARDIOMYOPATHY AND/OR RELATED HEART FAILURE AND PORTAL HYPERTENSIONFiled as MADRIGAL PHARMACEUTICALS, INC.2025-11-12REBECCA TAUB | pending |
| Resmetirom Therapy of MASH-Associated Child Pugh A CirrhosisFiled as Madrigal Pharmaceuticals, Inc.2025-09-03REBECCA TAUB | pending |
| SOLID FORMS OF 2-(3,5-DICHLORO-4-((5-ISOPROPYL-6-OXO-1,6-DIHYDROPYRIDAZIN-3-YL)OXY)PHENYL)-3,5-DIOXO-2,3,4,5-TETRAHYDRO-1,2,4-TRIAZINE-6-CARBONITRILEC07D 403/12, A61P 19/00, A61P 1/16, A61P 3/00, A61P 3/06, A61P 5/14, A61K 9/14, A61K 31/53, A61K 47/32, C07B2200/13Filed as Madrigal Pharmaceuticals, Inc.2025-08-19Mahmoud MIRMEHRABI | pending |
| USE OF THYROID HORMONE RECEPTOR BETA AGONISTS FOR THE TREATMENT OF CARDIOMYOPATHY AND HEART FAILUREFiled as Madrigal Pharmaceuticals, Inc.2025-07-18CHRISTOPHER DADAS | pending |
| METHODS FOR TREATING A FATTY LIVER DISEASEFiled as Madrigal Pharmaceuticals, Inc.2025-07-10REBECCA TAUB | pending |
| METHODS FOR TREATING A FATTY LIVER DISEASEFiled as Madrigal Pharmaceuticals, Inc.2025-07-09REBECCA TAUB | pending |
| TREATMENT USING RESMETIROM AND GLP-1/GIP RECEPTOR AGONISTSFiled as Madrigal Pharmaceuticals, Inc.2025-07-07REBECCA TAUB | pending |
| METHODS FOR TREATING A FATTY LIVER DISEASEFiled as Madrigal Pharmaceuticals, Inc.2025-05-22REBECCA TAUB | pending |
| METHODS FOR TREATING A FATTY LIVER DISEASEFiled as Madrigal Pharmaceuticals, Inc.2025-05-14REBECCA TAUB | pending |
| METHODS FOR TREATING A FATTY LIVER DISEASEFiled as Madrigal Pharmaceuticals, Inc.2025-05-13REBECCA TAUB | pending |
| METHODS FOR TREATING A FATTY LIVER DISEASEFiled as Madrigal Pharmaceuticals, Inc.2025-05-09REBECCA TAUB | pending |
| METHODS FOR TREATING A FATTY LIVER DISEASEFiled as Madrigal Pharmaceuticals, Inc.2025-05-08REBECCA TAUB | pending |
| METHODS FOR TREATING A FATTY LIVER DISEASEFiled as MADRIGAL PHARMACEUTICALS, INC.2025-02-05REBECCA TAUB | pending |
| METHODS FOR TREATING A FATTY LIVER DISEASEA61P 1/16, A61K 31/53Filed as Madrigal Pharmaceuticals, Inc.2025-02-04REBECCA TAUB | 12377104 |
| METHODS FOR TREATING A FATTY LIVER DISEASEFiled as Madrigal Pharmaceuticals, Inc.2024-11-16REBECCA TAUB | pending |
| SOLID FORMS OF 2-(3,5-DICHLORO-4-((5-ISOPROPYL-6-OXO-1,6-DIHYDROPYRIDAZIN-3-YL)OXY)PHENYL)-3,5-DIOXO-2,3,4,5-TETRAHYDRO-1,2,4-TRIAZINE-6-CARBONITRILEC07D 403/12, A61P 19/00, A61P 1/16, A61P 3/00, A61P 3/06, A61P 5/14, A61K 9/14, A61K 31/53, A61K 47/32, C07B2200/13Filed as Madrigal Pharmaceuticals, Inc.2024-11-15Mahmoud MIRMEHRABI | pending |
| METHODS FOR TREATING A FATTY LIVER DISEASEFiled as Madrigal Pharmaceuticals, Inc.2024-11-14REBECCA TAUB | pending |
| METHODS FOR TREATING A FATTY LIVER DISEASEFiled as Madrigal Pharmaceuticals, Inc.2024-11-12REBECCA TAUB | pending |
| NOVEL THR BETA ANALOGS AND USES THEREOFC07D 401/12, C07D 403/12, A61P 1/16, A61P 3/06, A61P 5/14, A61K 31/513Filed as MADRIGAL PHARMACEUTICALS, INC.2024-08-09JAMES K. HENNAN | pending |
| BIOMARKERS FOR TREATING LIVER DISORDERS WITH THR-AGONISTS AND RELATED USESFiled as MADRIGAL PHARMACEUTICALS, INC.2024-06-20REBECCA TAUB | pending |
| BIOMARKERS FOR TREATING LIVER DISORDERS WITH THR-B AGONISTS AND RELATED USESA61K 31/53, A61P 1/16, G01N 33/78, G01N2333/59, G01N2800/085, G01N2800/52Filed as Madrigal Pharmaceuticals, Inc.2024-06-20Rebecca TAUB | pending |
| METHODS FOR TREATING A FATTY LIVER DISEASEFiled as Madrigal Pharmaceuticals, Inc.2024-06-04REBECCA TAUB | pending |
| RESMETIROM FOR REDUCING LIVER VOLUMEA61K 31/501, A61K 31/53, A61P 1/16Filed as Madrigal Pharmaceuticals, Inc.2024-03-26REBECCA TAUB | pending |
| METHODS FOR TREATING A FATTY LIVER DISEASEFiled as Madrigal Pharmaceuticals, Inc.2024-03-13REBECCA TAUB | pending |
| TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) WITH LIVER FIBROSISFiled as Madrigal Pharmaceuticals, Inc.2024-02-06REBECCA TAUB | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on MDGL
Company overviewEverything on MDGL in one place, with the price.SEC filingsWhat MDGL's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat MDGL's own officers and directors buy and sell.Planned salesSales MDGL insiders have filed notice of.Who owns itEvery manager reporting a position in MDGL.Funds holding itWhich funds and ETFs hold MDGL, and how big a bet.LobbyingWhat MDGL spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on MDGL's account, and who they worked for.Federal contractsWhat federal agencies pay MDGL.